| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | JW-74 | CTRPv2 | pan-cancer | AAC | 0.2 | 9e-06 |
| mRNA | nintedanib | CTRPv2 | pan-cancer | AAC | 0.16 | 1e-05 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.13 | 2e-05 |
| mRNA | KIN001-260 | GDSC1000 | pan-cancer | AAC | 0.13 | 3e-05 |
| mRNA | Axitinib | GDSC1000 | pan-cancer | AAC | 0.14 | 4e-05 |
| mRNA | BRD-K09344309 | CTRPv2 | pan-cancer | AAC | 0.29 | 5e-05 |
| mRNA | Dasatinib | CTRPv2 | pan-cancer | AAC | 0.14 | 6e-05 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | 0.15 | 9e-05 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0001 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0001 |